Current concepts on the etiology, pathogenesis, and treatment of Dupuytren's disease (literature review)
https://doi.org/10.25789/YMJ.2026.93.22
Abstract
Dupuytren's disease is one of the most common hand disorders, leading to limitations of hand function. In recent years, there has been an increase in the number and a significant decrease in the age of patients. Long-term treatment outcomes for patients with this disease are often unsatisfactory. This is primarily due to a lack of information on current, effective treatment technologies. The aim of this study is to improve the effectiveness of treatment for patients with Dupuytren's disease by informing a wide range of practicing physicians about current views on its etiology, pathogenesis, and treatment technologies. A search and selection of publications in the RSCI, PubMed, Cochrane, and Scopus databases over the past 6 years revealed fragmentary knowledge of the disease's pathogenesis and the lack of a valid laboratory model, which hinders the development of pathogenetic drug treatment. The lack of a generally accepted study design for this problem and a system for evaluating the obtained results hinders the ability to objectively compare the results of various scientific studies. An analysis of the effectiveness of the applied technologies of conservative and surgical treatment is conducted. The emergence in recent years of the first pharmacological drugs for injection therapy with pathogenetic action, which have proven their clinical effectiveness, is a major step forward in the treatment of Dupuytren's disease.
About the Authors
V. A. Malchevskiy
ФГБОУ ВО «Тюменский Государственный медицинский университет» Министерства здравоохранения Российской Федерации
Russian Federation
Russian Federation
N. I. Karpovich
ФГБОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы» Министерства образования Российской Федерации
Russian Federation
Russian Federation
A. V. Malchevskiy
ФГБОУ ВО «Тюменский Государственный медицинский университет» Министерства здравоохранения Российской Федерации
Russian Federation
Russian Federation
References
1. Coulibaly N.F., Doumbia M.M., Dembele B., et al. Dupuytren's disease: A reality in Black Africa. Hand Surgery and Rehabilitation. 2020; 39(5): 448-453. https://doi.org/10.1016/j.hansur.2020.04.005.
2. Kordahi A.M., Unadkat J.V. Dupuytren’s Contracture: Approach to Treatment and Counseling Patients in 2024. Clinics in Plastic Surgery. 2024; 51(4): 527-537. https://doi.org/10.1016/j. cps.2024.05.002.
3. Simón-Pérez C., Rodríguez-Mateos J.I., Maestro I.A. Long-term recurrence of Dupuytren's disease treated with clostridium histolitycum collagenase. Surgical treatment and anatomopathological study. Arch Orthop Trauma Surg. 2024; 144(5): 2085-2091. https://doi.org/10.1007/s00402-024-05320-7.
4. Ovchinnikova E.K., Gilfanov S.I. The possibility of effective using the conservative and the minimally invasive treatment methods at various stages of the Dupuytren disease. Journal of Clinical Practice. 2024; 15(4): 97–103 (In Russian). https://doi.org/10.17816/clinpract641980
5. Alser O., Craig R.S., Lane J.C.E., et al. Serious complications and risk of re-operation after Dupuytren's disease surgery: a population-based cohort study of 121,488 patients in England. Sci Rep. 2020; 10(1): 16520. https://doi.org/10.1038/s41598-020-73595-y.
6. Salari N., Heydari M., Hassanabadi M., et al. The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2020; 15(1): 495. https://doi.org/10.1186/s13018-020-01999-7.
7. Aissvarya S., Ling K. H., Arumugam M., Thilakavathy K. Molecular genetics of Dupuytren’s contracture. EFORT Open Reviews. 2024; 9(8): 723-732. https://doi.org/10.1530/EOR-23-0056.
8. Dent C., Coutelle N., Gill M., et al. Clinical Effectiveness of an Orthosis After Collagenase Clostridium Histolyticum Injection for Dupuytren Contracture. The Journal of Hand Surgery. 2025; 50(5): 547-553. https://doi.org/10.1016/j.jhsa.2025.01.023.
9. Dutta A., Jayasinghe G., Deore S., et al. Dupuytren’s Contracture – Current Concepts. Journal of Clinical Orthopaedics and Trauma. 2020; 11(4): 590-596. https://doi.org/10.1016/j.jcot.2020.03.026.
10. Nann S., Kovoor J., Fowler J., et al. Surgical management of Dupuytren disease: a systematic review and network meta-analyses. Hand. 2023; 19(8): 1283-1292. https://doi.org/10.1177/15589447231174175.
11. Boe C, Blazar P, Iannuzzi N. Dupuytren Contractures: An Update of Recent Literature. The Journal of Hand Surgery. 2021; 46(10): 896- 906. https://doi.org/10.1016/j.jhsa.2021.07.005.
12. Ng M., Lawson D.J., Winney B., Furniss D. Is Dupuytren's disease really a ‘disease of the Vikings’? J Hand Surg Eur. 2020; 45(3): 273-279. https://doi.org/10.1177/1753193419882851.
13. Putnam J. Advanced Dupuytren Contracture: Approach to Management. Hand Clinics. 2023; 39(3): 455-463. https://doi.org/10.1016/j.hcl.2023.03.006.
14. Williams S., Hobby J. Dupuytren's disease. Surgery (Oxford). 2025; 43(2): 120-126. https://doi.org/10.1016/j.mpsur.2024.11.004.
15. Zhang D., Earp B.E., Benavent K.A., Blazar P. Collagenase treatment of Dupuytren's disease with minimum 5-year follow-up: recurrence, reintervention, and satisfaction. Plast Reconstr Surg. 2020; 146(5): 1071-1079. https://doi.org/10.1097/PRS.0000000000007243.
16. Shchudlo N.A., Varsegova T.N., Stupina T.A., Shchudlo M.M. Types and stages of vascular remodeling in Dupuytren's contracture (analysis of 506 arteries in the surgical material of 111 patients). Genij Ortopedii. 2020; 26(2): 179-184 (In Russian). https://doi.org/10.18019/1028-4427-2020-26-2-179-184.
17. Shchudlo N.A., Stupina T.A., Shchudlo M.M., Ostanina D.A. Comparative clinical and pathomorphological characteristics of Dupuytren’s contracture in men and women. Traumatology and Orthopedics of Russia. 2021; 27(1): 166-174 (In Russian). https://doi.org/10.21823/2311-2905-2021-27-1-166-174.
18. Cha R.C., Chung J.S., Ramtin S., Ilyas A.M. Determining Risk Factors and Rate of Surgery After Collagenase Injections for Dupuytren Contracture. Journal of Hand Surgery Global Online. 2025; 7(5): 100768. https://doi.org/10.1016/j.jhsg.2025.100768.
19. Steppe C., Cinclair R., Lies S. A 10-year review of collagenase versus fasciectomy in the treatment of Dupuytren contracture. Ann Plast Surg. 2024; 92(6): 642-646. https://doi.org/10.1097/SAP.0000000000003913.
20. Van den Berge B.A., Werker P.M.N., Broekstra D.C. Limited progression of subclinical Dupuytren's disease. Bone Joint Lett J. 2021; 103-B(4): 704-710. https://doi.org/10.1302/0301-620X.103B4.BJJ-2020-1364.R1.
21. Liechti R., Bernhard J., Merky D.N., et al. Early postinterventional clinical implications of Collagenase Clostridium Histolyticum injection versus limited fasciectomy for Dupuytren's disease. Journal of Hand and Microsurgery. 2025; 17(4): 100268. https://doi.org/10.1016/j.jham.2025.100268.
22. Rajpar N.A., Khaskheli S.A., Abbasi S., et al. “Collagenase injections versus limited fasciectomy in treating patients with Dupuytren's contracture: A systematic review and meta-analysis”. International Journal of Orthopaedic and Trauma Nursing. 2025; 58: 101211. https://doi.org/10.1016/j.ijotn.2025.101211.
23. Sarkar M, Kashyap N, Madabhavi I. Dupuytren’s disease: A review. Chinese Journal of Plastic and Reconstructive Surgery. 2024; 6(3): 142- 148. https://doi.org/10.1016/j.cjprs.2024.08.002.
24. Wong C.R., Huynh M.N.Q., Fageeh R., McRae M.C. Outcomes of management of recurrent Dupuytren contracture: a systematic review and meta-analysis. Hand (N Y). 2022; 17(6): 1104-1113. https://doi.org/10.1177/1558944721994220.
25. Yunes M.J. Radiation Therapy for Dupuytren Contracture. Practical Radiation Oncology. 2025; 15(3): 248-252. https://doi.org/10.1016/j.prro.2024.11.010.
26. Ruettermann M., Hermann R.M., Khatib-Chahidi K., Werker P.M.N. Dupuytren's disease-Etiology and treatment. Dtsch Arztebl Int. 2021; 118(46): 781-788. https://doi.org/10.3238/arztebl.m2021.0325.
27. Kemler M.A., De Wijn R.S., Van Rijssen A.L., et al. Dutch Multidisciplinary Guideline on Dupuytren Disease. Journal of Hand Surgery Global Online. 2023; 5(2): 178-183. https://doi.org/10.1016/j.jhsg.2022.11.008.
28. Grebenyuk L.A., Gryaznykh A.V., Shabalin D.A., Ostanina D.A. Functional overload of the hand, development of Dupuytren's contracture, and biomechanical monitoring of tissues under severe disease conditions. Human. Sport. Medicine. 2023; 23(S1): 119–126 (In Russian). https://doi.org/10.14529/hsm23s117.
29. Dmitriev S.V., Berezutskiy S.N., Volovik V.E. Intraoperative and early postoperative complications in the treatment of patients with Dupuytren's contracture. Literature review. Public Health of the Far East. 2024; 4(102): 54-60 (In Russian). https://doi.org/10.33454/1728-1261-2024-4-54-60.
30. Stupina T.A., Shchudlo N.A., Varsegova T.N., Ostanina D.A. Pathogenetic and clinical significance of fungal infection of the palmar aponeurosis in Dupuytren's contracture. Genij Ortopedii. 2024; 30(1): 59-66 (In Russian). https://doi.org/10.18019/1028-4427-2024-30-1-59-66.
31. Almadani Y.H., Vorstenbosch J., Efanov J.I., Xu L. Dupuytren's disease: an outcomes-focused update. Semin Plast Surg. 2021; 35(3): 216- 222. https://doi.org/10.1055/s-0041-1731631.
32. Nanchahal J.,∙Ball C., Rombach I., et al. Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2022; 4(6): E407-E416. https://doi.org/10.1016/S2665-9913(22)00093-5.
33. Yazdani A., Nasri P., Mahdavi S.B. The Effects of Shock Wave Therapy on the Symptoms and Function of Individuals With Dupuytren Disease: A Systematic Review. Archives of Physical Medicine and Rehabilitation. 2024; 105(10): 1985-1992. https://doi.org/10.1016/j. apmr.2024.05.030.
34. Lambi A.G., Popoff S.N., Benhaim P., Barbe M.F. Pharmacotherapies in Dupuytren Disease: Current and Novel Strategies. The Journal of Hand Surgery. 2023; 48(8): 810-821. https://doi.org/10.1016/j.jhsa.2023.02.003
35. Shchudlo N.А., Stupina T.A., Varsegova T.N., Ostanina D.A. The role of mast cells in the progression of Dupuytren's contracture. The Genius of Orthopaedics". 2023; 29(3): 265-269 (In Russian). https://doi.org/10.18019/1028-4427-2023-29-3-265-269.
36. Medvedev G.V., Pushkin D.V., Orlov A.R., Petrov A.V., et al. Scales and questionnaires for the diagnosis of Dupuytren’s disease. Vestnik of Saint-Petersburg University. Medicine. 2024; 19(1): 14–27 (In Russian). https://doi.org/10.21638/spbu11.2024.102
37. Ovchinnikova E.K., Gilfanov S.I., Markina N.Y. Ultrasound parameters of palmar fibromatosis or Dupuytren’s contracture. Avicenna Bulletin. 2025; 27(2): 472-478 (In Russian). https://doi.org/10.25005/20740581-2025-27-2-472-478.
38. Martins-Bach A.B., Bachasson D., Araujo E.C.A., et al. Non-invasive assessment of skeletal muscle fibrosis in mice using nuclear magnetic resonance imaging and ultrasound shear wave elastography. Sci Rep. 2021; 11(1): 284. https://doi.org/10.1038/s41598-020-78747-8.
39. Davis S.M., Chang E.Y. Dupuytren's contracture treated with botulinum toxin A injection. Arch Clin Cases. 2021; 7(4): 63-67. https://doi.org/10.22551/2020.29.0704.10175.
40. Dias J., Tharmanathan P., Arundel C. Collagenase injection versus limited fasciectomy for Dupuytren's contracture. New Engl J Med. 2024; 391(16): 1499-1510. https://doi.org/10.1056/NEJMoa2312631.
41. De Ketele A., Degreef I. Full-thickness skin grafting in preventing recurrence of Dupuytren's disease: a systematic review. Hand Surg Rehabil. 2023; 42(4): 273-283. https://doi.org/10.1016/j.hansur.2023.06.002.
42. Karam M., Kahlar N., Abul A., et al. Comparison of hand therapy with or without splinting postfasciectomy for Dupuytren's contracture: systematic review and meta-analysis. J Hand Microsurg. 2021; 14(4): 308-314. https://doi.org/10.1055/s-0041-1725221.
43. Denkler K.A., Park K.M., Alser O. Treatment options for Dupuytren's disease: tips and tricks. Plast Reconstr Surg Glob Open. 2022; 10(1): e4046. https://doi.org/10.1097/GOX.0000000000004046.
44. Dent C., Coutelle N., Moore A., et al. Clinical Outcomes of Collagenase Injections in Management of Dupuytren Contracture of the Proximal Interphalangeal Joint. Journal of Hand Surgery Global Online. 2024; 6(5): 627-630. https://doi.org/10.1016/j.jhsg.2024.05.009.
45. Harryson M., Eklund M., Arner M., Wilbrand S. Patient-Reported Outcome in Dupuytren’s Disease Treated With Fasciectomy, Collagenase or Needle Fasciotomy: A Swedish Registry Study. Journal of Hand Surgery Global Online. 2023; 5(6): 733-739. https://doi.org/10.1016/j.jhsg.2023.06.009.
46. Warwick D., Werker P. N., Pess G., et al. Dupuytren's disease: using needles more across the world. J Hand Surg Eur. 2022; 47(1): 80-88. https://doi.org/10.1177/17531934211043307.
47. Ashdown T., Hayter E., Morris J.A., Repeat limited fasciectomy is a safe and effective treatment for recurrence of Dupuytren's disease. Bone Jt J. 2021; 103-B(5): 946-950. https://doi.org/10.1302/0301-620X.103B5.BJJ-2020-1393. R2.
48. Idrisov Kh.K., Rodomanova L.A. Skin closure after subtotal aponeurectomy in severe Dupuytren’s contracture: Review. Traumatology and Orthopedics of Russia. 2022; 28(2): 114- 123 (In Russian). https://doi.org/10.17816/2311- 2905-1767.
49. Shchudlo N.A., Stupina T.A., Varsegova T.N., Ostanina D.А. Histological features of fascial fibromatosis in patients with rapidly progressive Dupuytren’s contracture. Traumatology and Orthopedics of Russia. 2025; 31(3): 111-120 (In Russian). https://doi.org/10.17816/2311290517664.
Review
For citations:
Malchevskiy V.A., Karpovich N.I., Malchevskiy A.V. Current concepts on the etiology, pathogenesis, and treatment of Dupuytren's disease (literature review). Yakut Medical Journal. 2026;(1):105-110. (In Russ.) https://doi.org/10.25789/YMJ.2026.93.22
Views:
48
JATS XML
Email this article 